<DOC>
	<DOCNO>NCT01478282</DOCNO>
	<brief_summary>The main goal study improve safety efficiency clinical practice new generation oral anticoagulant . 1 . To determine effect new oral anticoagulant ( dabigatran rivaroxaban ) platelets coagulation mechanism flow condition . 2 . To evaluate ability concentrate contain coagulation factor ( PCCs FVIIa ) reverse effect induce new anticoagulant . These study carry ex vivo blood sample obtain healthy volunteer undergo oral anticoagulant therapy dos prove efficacy safety use previous clinical trial .</brief_summary>
	<brief_title>Reversal Antithrombotic Action New Oral Anticoagulants</brief_title>
	<detailed_description>There lack information antidote could reverse effect new oral anticoagulant patient require rapid restoration impair hemostatic mechanism . The present study seek improve security efficacy clinical practice new generation oral anticoagulant . OBJECTIVES : 1 . To assess action new oral anticoagulant ( dabigatran rivaroxaban ) hemostasis specific interest possible interference platelet interaction coagulation mechanism flow condition ; 2 . To evaluate comparatively effect coagulation factor concentrate establish efficacy ( prothrombin complex rFVIIa ) reverse alteration hemostasis parameter induce new anticoagulant . METHODOLOGY : Studies perform ex vivo use blood sample healthy individual subject treatment new anticoagulant dose proven efficacy safety ( 150mg/12 h dabigatran 20 mg/day rivaroxaban ) . Blood sample participant spike `` vitro '' know concentration coagulation factor . Modifications : - morphometric parameter ( platelet deposition fibrin formation ) perfusion study flow condition ; - analytical test evaluate change coagulation mechanism ( thrombin generation , ecarine prothrombin time ) determine .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Healthy volunteer age 21 60 year Approval inform consent History hepatic kidney disease Previous history hemorrhagic thrombotic disease Pregnancy breast feeding Concomitant use drug affect hemostasis Use medication herbal treatment could interfere pharmacokinetics pharmacodynamics study drug ( accord manufacturer label ) Practice risky sport ( study period ) Blood donation previous 3 month</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>dabigatran</keyword>
	<keyword>rivaroxaban</keyword>
	<keyword>oral anticoagulant</keyword>
	<keyword>coagulation</keyword>
	<keyword>bleeding</keyword>
	<keyword>plasma concentrate</keyword>
</DOC>